Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study.

Xu, Su-Mei; Chang, Li-Wen; Tsai, Cheng-Yuan; Liu, Wan-Li; Li, Dai; Li, Shan-Shan; Li, Xiao-Min; Xu, Ping-Sheng

Xu, Su-Mei; Chang, Li-Wen; Tsai, Cheng-Yuan; Liu, Wan-Li; Li, Dai; Li, Shan-Shan; Li, Xiao-Min; Xu, Ping-Sheng.

Afiliação

Xu SM; Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, China.
Chang LW; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Tsai CY; TaiGen Biotechnology Co., Ltd., Taipei, China.
Liu WL; TaiGen Biotechnology Co., Ltd., Taipei, China.
Li D; Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, China.
Li SS; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Li XM; Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, China.
Xu PS; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Front Pharmacol ; 14: 1272466, 2023.

Article em En | MEDLINE | ID: mdl-38027026

Palavras-chave

TG-1000; first-in-human; influenza; pharmacokinetics; safety; tolerability

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google